|1.||Crawford, Jeffrey: 11 articles (10/2015 - 01/2002)|
|2.||Lyman, Gary H: 7 articles (10/2015 - 01/2002)|
|3.||Abraham, Ivo: 5 articles (02/2016 - 03/2011)|
|4.||Turner, Matthew: 5 articles (02/2016 - 03/2011)|
|5.||Weycker, Derek: 5 articles (01/2014 - 03/2006)|
|6.||Balducci, Lodovico: 5 articles (10/2013 - 01/2002)|
|7.||Malin, Jennifer: 5 articles (06/2012 - 05/2007)|
|8.||Fridman, Moshe: 5 articles (03/2007 - 03/2003)|
|9.||Prous, J R: 5 articles (12/2006 - 06/2004)|
|10.||Rabasseda, X: 5 articles (12/2006 - 06/2004)|
11/01/1994 - "We conclude that R-metHUG-CSF is very effective in shortening the duration of neutropenia in the immediate post-BMT period with lesser BMT morbidity, earlier discharge from hospital and lower cost of BMT. "
05/01/2008 - "During anti-HCV therapy, filgrastim improved neutropenia and darbepoetin alpha improved both anaemia and quality of life. "
09/01/2015 - "This study demonstrates that biosimilar and the reference filgrastim are similar with no clinically meaningful differences regarding efficacy and safety in prevention of severe neutropenia. "
01/01/2009 - "In the two registrational studies of filgrastim, the cumulative incidence of febrile neutropenia (FN) was reduced by about 50% compared with placebo. "
01/01/2009 - "Patients with neutropenia and malignancy who were required to receive filgrastim were eligible for the study. "
08/01/2001 - "Six months after the beginning of the trial, filgrastim had not reduced the number of deaths, the number of hospital days, or the risk of bacterial or fungal infection. "
03/01/2014 - "The primary outcomes were time from initiation of filgrastim to recovery of stable neutrophil count of >500 cells/µL and a composite clinical outcome of infection or death assessed for the first course post-randomization. "
08/01/2007 - "The history of severe infection and hospitalization at presentation was significantly more common among the patients who received filgrastim than those observed, but was not different between the 2 groups during the follow-up period. "
03/01/2007 - "Patients aged > 60 years or with increased infection risk received filgrastim 5 microg/kg per day in all R-CHOP cycles; other patients received filgrastim after a neutropenic event (no planned administration for cycle 1). "
01/01/2004 - "These results suggest that Filgrastim treatment reinforces innate immunity, enabling better prevention of infection. "
|3.||Breast Neoplasms (Breast Cancer)
11/01/1999 - "CP followed by filgrastim is a safe and effective regimen for the mobilization of PBPCs in patients with breast cancer and shows significant activity in patients who failed to mobilize with filgrastim, suggesting a higher mobilization potential."
09/01/2013 - "The efficacy and safety of FSK0808, filgrastim biosimilar: a multicenter, non-randomized study in Japanese patients with breast cancer."
01/01/2002 - "A cost benefit associated with the use of filgrastim in patients with breast cancer has been realised. "
11/01/1999 - "Sixty-four patients with stage II-IV breast cancer received (CP) followed by filgrastim (10 microg/kg/day). "
05/01/1999 - "In this paper, the advantages and disadvantages of these strategies will be discussed, and the results of a recently conducted, randomized, controlled phase 3 clinical trial in breast cancer patients receiving either SCF plus filgrastim or filgrastim alone for PBPC mobilization will be reviewed."
05/15/2003 - "CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial."
07/01/2015 - "With the aim of assessing the efficacy and the safety of filgrastim biosimilars in post-ASCT bone marrow recovery, we conducted a single institution, retrospective study in 56 lymphoma and myeloma patients who received filgrastim biosimilars (Tevagrastim(®) and Zarzio(®)) at standard doses from day 5. We compared our results with recently published data on the originator. "
01/01/2014 - "We identified 65 patients with lymphoma or myeloma treated with filgrastim biosimilars for ASCT and compared 19 parameters of these patients, including BM recovery, side effects, infectious complications and treatment costs, with published historical data on a cohort of 50 patients treated with classic filgrastim. "
01/01/2014 - "We conducted a single-center retrospective study in patients with lymphoma and myeloma treated at Brest Hospital to assess the cost reductions related to and the efficiency and safety of filgrastim biosimilars. "
03/01/2013 - "Thirty historical controls (lymphoma n=18; myeloma n=12) received filgrastim 10 mcg/kg daily from D1. "
|5.||Non-Hodgkin Lymphoma (Lymphosarcoma)
03/01/2007 - "This community-based study was conducted to determine response, toxicity, and disease-free survival in patients with intermediate-or high-grade non-Hodgkin lymphoma receiving R-CHOP with filgrastim. "
01/01/2005 - "A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma."
10/01/1997 - "Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). "
01/01/2002 - "Treatment of aggressive non-Hodgkin's lymphoma with chemotherapy in combination with filgrastim."
10/01/1997 - "Filgrastim increases leukocyte and neutrophil counts and dose intensity, if used with CEOP/IMVP-Dexa chemotherapy in high-grade lymphomas. "
|1.||Granulocyte Colony-Stimulating Factor (G-CSF)
|9.||Anti-Bacterial Agents (Antibiotics)
|1.||Drug Therapy (Chemotherapy)
|2.||Transplantation (Transplant Recipients)
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|4.||Stem Cell Transplantation